The publication in a reputable journal like the Journal of the American Heart Association increases the credibility of Zyversa's research on NLRP3 inflammasomes and their link to peripheral arterial disease. This may lead to increased interest in their research and potential collaborations or partnerships, positively impacting their stock price in the short term.